Molecular biomarkers for predicting complete response to preoperative chemoradiation in people with locally advanced rectal cancer

Penelope A De Lacavalerie; Sarah J Lord; Matthew J Morgan; Catherine E Caldon; Maija Rj Kohonen-Corish

doi:10.1002/14651858.CD014718

Molecular biomarkers for predicting complete response to preoperative chemoradiation in people with locally advanced rectal cancer

Cochrane Database Syst Rev. 2024 Nov 29;11(11):CD014718. doi: 10.1002/14651858.CD014718.

Authors

Penelope A De Lacavalerie^{1

2

3

4}, Sarah J Lord^{5

6}, Matthew J Morgan^{7

8}, Catherine E Caldon^{1

2}, Maija Rj Kohonen-Corish^{1

9

10

11}

Affiliations

¹ Cancer Theme, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
² St Vincent's Clinical School, UNSW Medicine, UNSW Sydney, Darlinghurst, NSW, Australia.
³ Department of Surgery, Northern Beaches Hospital, Sydney, NSW, Australia.
⁴ Department of Surgery, Prince of Wales Private Hospital, Sydney, NSW, Australia.
⁵ NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
⁶ School of Medicine, University of Notre Dame, Darlinghurst, NSW, Australia.
⁷ Department of Surgery, Bankstown Hospital, Sydney, NSW, Australia.
⁸ Southwest Clinical School, UNSW Sydney, Bankstown, NSW, Australia.
⁹ Woolcock Institute of Medical Research, Sydney, NSW, Australia.
¹⁰ Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.
¹¹ School of Medicine, Western Sydney University, Sydney, NSW, Australia.

PMID: 39611427
PMCID: PMC11605794 (available on 2025-11-29)
DOI: 10.1002/14651858.CD014718

Abstract

This is a protocol for a Cochrane Review (prognosis). The objectives are as follows: Primary objectives To identify and estimate the prognostic value of molecular biomarkers as predictors of pathological complete response to neoadjuvant chemoradiotherapy in people with locally advanced rectal cancer. summarises the review question in population, index prognostic factor, comparator prognostic factor(s), outcome, timing, and setting (PICOTS) format. [Table: see text] [Figure: see text] Secondary objectives To explore the following biomarker measurement, treatment, and study design factors as possible sources of heterogeneity in the association between the prognostic factor and pathological response: type of assay/measurement method, biomarker positivity criteria or cut-off point, chemotherapy regimen, and radiotherapy regimen.

MeSH terms

Biomarkers, Tumor / blood
Chemoradiotherapy* / methods
Humans
Neoadjuvant Therapy* / methods
Prognosis
Randomized Controlled Trials as Topic
Rectal Neoplasms* / pathology
Rectal Neoplasms* / therapy

Substances

Biomarkers, Tumor